Wilms Tumor Study
COG # AREN0532 Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor
Protocol ID
07.10.099
Protocol Description
The overall goal of this study is:
- To find out if some subjects with a higher risk of having their Wilms tumor return will benefit from the addition of doxorubicin to the current standard treatment regimen. This is experimental treatment.
- To find out if there are things about the tumor cells that might tell us why standard treatment does not get rid of the tumor for all Stage I, II or III Wilms tumor of some patients .
Eligibility Criteria
Children and adolescents with Wilms tumor
Primary Investigator(s)
- Arlene Redner, MD